235 related articles for article (PubMed ID: 25418946)
21. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.
Kyrkanides S; Miller JH; Brouxhon SM; Olschowka JA; Federoff HJ
Brain Res Mol Brain Res; 2005 Feb; 133(2):286-98. PubMed ID: 15710246
[TBL] [Abstract][Full Text] [Related]
22. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
Savas PS; Hemsley KM; Hopwood JJ
Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
[TBL] [Abstract][Full Text] [Related]
23. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
24. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
25. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
27. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
28. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
Hemsley KM; King B; Hopwood JJ
Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
[TBL] [Abstract][Full Text] [Related]
29. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA.
King B; Savas P; Fuller M; Hopwood J; Hemsley K
Mol Genet Metab; 2006 Feb; 87(2):107-12. PubMed ID: 16352454
[TBL] [Abstract][Full Text] [Related]
30. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice.
Fu H; Kang L; Jennings JS; Moy SS; Perez A; Dirosario J; McCarty DM; Muenzer J
Gene Ther; 2007 Jul; 14(14):1065-77. PubMed ID: 17460717
[TBL] [Abstract][Full Text] [Related]
31. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
32. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder.
Lau AA; Rozaklis T; Ibanes S; Luck AJ; Beard H; Hassiotis S; Mazouni K; Hopwood JJ; Kremer EJ; Hemsley KM
Gene; 2012 Jan; 491(1):53-7. PubMed ID: 21963444
[TBL] [Abstract][Full Text] [Related]
33. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain.
Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ
Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice.
Lau AA; Hannouche H; Rozaklis T; Hassiotis S; Hopwood JJ; Hemsley KM
Exp Neurol; 2010 Oct; 225(2):445-54. PubMed ID: 20673764
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
[TBL] [Abstract][Full Text] [Related]
36. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
Kaidonis X; Byers S; Ranieri E; Sharp P; Fletcher J; Derrick-Roberts A
Mol Genet Metab; 2016 Jun; 118(2):100-10. PubMed ID: 27106513
[TBL] [Abstract][Full Text] [Related]
37. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.
Sorrentino NC; D'Orsi L; Sambri I; Nusco E; Monaco C; Spampanato C; Polishchuk E; Saccone P; De Leonibus E; Ballabio A; Fraldi A
EMBO Mol Med; 2013 May; 5(5):675-90. PubMed ID: 23568409
[TBL] [Abstract][Full Text] [Related]
38. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
[TBL] [Abstract][Full Text] [Related]
39. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB.
Di Domenico C; Villani GR; Di Napoli D; Nusco E; Calì G; Nitsch L; Di Natale P
Am J Med Genet A; 2009 Jun; 149A(6):1209-18. PubMed ID: 19449420
[TBL] [Abstract][Full Text] [Related]
40. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
